Jul 2014

E Keppra® Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over


  • Approval of E Keppra® IV Drip Infusion use will enable uninterrupted treatment of patients temporarily unable to swallow oral E Keppra® formulations. This product has been approved in over 40 countries and regions including in the EU and US in 2006.
  • About 1% of people worldwide have epilepsy, and onset of new cases is particularly high in infants and the elderly. About 70% of patients can live seizure-free lives if they are able to continuously take anti-epileptic drugs.
  • E Keppra® (brand name outside Japan is Keppra®) was first approved in the US in 1999 and has received approval in more than 100 countries and regions. It is a novel anti-epileptic drug prescribed to patients ranging from children to the elderly. It has been used by more than 100,000 patients in Japan.

Otsuka Pharmaceutical Co., Ltd. (headquarters: Tokyo; President and Representative Director: Taro Iwamoto;) and UCB Japan Co., Ltd. (headquarters: Tokyo; President and Representative Director: Joel Peterson) received marketing authorization in Japan on July 4, 2014, 2014 for E Keppra® for IV Drip Infusion 500 mg (levetiracetam). E Keppra® IV Drip Infusion is an alternative for patients who are temporarily unable to take oral formulations of E Keppra®.

Information in this news release was current as of the original release date.


Otsuka Pharmaceutical Co., Ltd. (OPC) is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. 

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. 

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada. OCPI aims to improve the quality of life and health of patients through its commitments to neuroscience, cardiovascular health, oncology and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent, Quebec.


OCPI is part of Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately CAD 14.5 billion (USD 11 billion) in 2016.

About Us
Contact Us

1 888 997-9017
514 332-3001

2250 Alfred-Nobel Boulevard,
St-Laurent, Quebec,
Suite 301
H4S 2C9